Bristol's drug pricing under fire as UK agency rejects Opdivo

LONDON (Reuters) - Bristol-Myers Squibb's closely watched new drug Opdivo, one of the first of a new wave of cancer medicines that boost the immune system, has been rejected as too expensive for treating lung cancer by Britain's cost watchdog.

http://ift.tt/1NwSva4

from Reuters: Health News
via animenewspro